Loading...

Freeline Therapeutics Holdings plc

FRLN•NASDAQ
Healthcare
Biotechnology
$6.49
$0.010(0.15%)
empty-state-iconFinancials data is not available for this stockFinancials details for this stock are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Over the past four quarters, Freeline Therapeutics Holdings plc demonstrated steady revenue growth, increasing from $0.00 in Q4 2022 to $5000.00 in Q3 2023. Operating income reached -$12.27M in Q3 2023, maintaining a consistent -245320% margin over recent quarters. Despite fluctuations in R&D and SG&A expenses, EBITDA remained robust at -$11.56M, reflecting operational efficiency. Net income rose to -$12.09M, with EPS at -$2.77. Disciplined expense management helped sustain profitability, highlighting solid overall financial performance.

Unlock 25+ Years of Financial Data

Get access to extended historical data, advanced metrics, and more with our premium plan

Frequently Asked Questions

;